Evidence map›Paper›PMID 22508158›Full record

ReviewNature reviews. Gastroenterology & hepatology2012

Acute and chronic pouchitis--pathogenesis, diagnosis and treatment.

Bo Shen

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Gastroenterology & hepatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05938465 (A Phase 1b/2 Study to Demonstrate the Safety and Efficacy of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an Ileal Pouch-Anal Anastomosis), which is not on this map. Cited by 62 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05938465 phase1 / phase2recruitingnot on this mapstarted 2023, after this paper: background citation

A Phase 1b/2 Study to Demonstrate the Safety and Efficacy of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an Ileal Pouch-Anal Anastomosis (PROF). The "PROF" Study.

TypeinterventionalSponsorExegi Pharma, LLCRan2023 to 2027Enrolled50ConditionsIleal PouchArmsEXE-346, Placebo
3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 1 synthesis or guideline pooled it, 150 citations in OpenAlex.

  1. Use of Biologics in Pouchitis: A Systematic Review.Journal of clinical gastroenterology · 2015
    Pooled it
  2. Trial
  3. Article
  4. Short- and long-term outcomes of IPAA for ulcerative colitis in Latin America: A retrospective, multicentre assessment.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2026
    Article
  5. A case of refractory pouchitis leading to cardiopulmonary arrest.Clinical journal of gastroenterology · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Approach to Therapy for Chronic Pouchitis.Annual review of medicine · 2025
    Review
  12. Observational
  13. Article
  14. Article
  15. Pouchitis: pathophysiology and management.Nature reviews. Gastroenterology & hepatology · 2024
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Bo ShenDepartment of Gastroenterology and Hepatology-A31, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44915, USA. shenb@ccf.org
Cleveland Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Restorative proctocolectomy with ileal pouch-anal anastomosis has become the procedure of choice for the majority of patients with ulcerative colitis who require surgical treatment. Pouchitis, the most common long-term complication of the procedure, involves a spectrum of disease processes with heterogeneous risk factors, clinical features, disease courses and prognoses. In addition, clinical symptoms of pouchitis are not specific and often overlap with those of other inflammatory and functional pouch disorders, such as Crohn's disease of the pouch and irritable pouch syndrome. Pouchoscopy and biopsy, along with laboratory and radiographic evaluations, are often required for accurate diagnosis in patients with symptoms indicative of pouchitis. Dysbiosis has been implicated as a triggering factor for pouchitis, and concurrent infection with pathogens, such as Clostridium difficile, might contribute to disease relapse and exacerbation. Antibiotic therapy is the main treatment modality. However, the management of antibiotic-dependent and antibiotic-refractory pouchitis remains challenging. Secondary causes of pouchitis, such as ischaemia, NSAID use, the presence of concurrent primary sclerosing cholangitis and other systemic immune-mediated disorders, should be evaluated and properly managed.

Indexed as

PouchitisAcute DiseaseAnti-Bacterial AgentsAnti-Inflammatory Agents, Non-SteroidalChronic DiseaseColitis, UlcerativeEnterocolitis, PseudomembranousHumansProctocolectomy, RestorativeAnti-Bacterial AgentsAnti-Inflammatory Agents, Non-Steroidal

Identifiers

PMID22508158
OpenAlexW2018568214

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.